Search - tctmd.com

Displaying 961 - 980 of 1179

Sort: Relevancy | Date

News Daily News

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Jason Kahn

July 17, 2012

News Daily News

Meta-analysis: Adjusting Therapy Based on Platelet Function Results Improves Outcomes

July 12, 2012

Presentation

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Presenter: Ryota Sakurai

July 12, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

News Daily News

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

July 10, 2012

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Daily News

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

July 03, 2012

News Daily News

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

June 26, 2012

News Industry News

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

June 26, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Daily News

Signs Point to Relationship Between Clopidogrel Efficacy, Cigarette Smoking

Yael L. Maxwell

June 20, 2012

News Daily News

Platelet Function Recovery Longer After Stopping Prasugrel Than Clopidogrel

June 14, 2012

News Daily News

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Caitlin E. Cox

June 07, 2012

News Daily News

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Caitlin E. Cox

June 07, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

June 05, 2012

News Daily News

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

June 05, 2012

News Daily News

Post-Conditioning Decreases Infarct Size, Edema after Reperfusion Therapy for STEMI

Leah Lawrence

June 05, 2012

Advertisement

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Meta-analysis: Adjusting Therapy Based on Platelet Function Results Improves Outcomes

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Signs Point to Relationship Between Clopidogrel Efficacy, Cigarette Smoking

Platelet Function Recovery Longer After Stopping Prasugrel Than Clopidogrel

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Rivaroxaban May be Cost-Effective for A-fib Patients

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

Post-Conditioning Decreases Infarct Size, Edema after Reperfusion Therapy for STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content